FFPE tissue specimens data from 40 surgically resected and metastatic GIST patients suggest a potential biomarker and prognostic value of both H19 and MALAT1 lncRNAs for the clinical selection of the best candidate to first-line treatment with imatinib (Badalamenti et al., 2019). Here, H19 is linked to gastrointestinal stromal tumor.